Incident opioid drug use and adverse respiratory outcomes among older adults with COPD

European Respiratory Journal

Volumn 48, Issue 3, 2016, Pages 683-693

  Vozoris, Nicholas T ^a,b,c   Wang, Xuesong ^d   Fischer, Hadas D ^d   Bell, Chaim M ^c,d,e,f   O'Donnell, Denis E ^g   Austin, Peter C ^d,e   Stephenson, Anne L ^a,b,c,e   Gill, Sudeep S ^d,g   Rochon, Paula A ^c,d,e,h  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f MOUNT SINAI HOSPITAL   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANILERIDINE; BENZODIAZEPINE; CODEINE; CODEINE PHOSPHATE; CODEINE SULFATE; DEXTROPROPOXYPHENE; FENTANYL; HYDROMORPHONE; LEVORPHANOL; MORPHINE; OPIATE; OXYCODONE; PARACETAMOL; PETHIDINE; BRONCHODILATING AGENT; NARCOTIC ANALGESIC AGENT;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG FORMULATION; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; ALGORITHM; COMPLICATION; FACTUAL DATABASE; HOSPITAL EMERGENCY SERVICE; MIDDLE AGED; MORTALITY; ONTARIO; OPIATE ADDICTION; PROBABILITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; PULMONOLOGY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANALGESICS, OPIOID; BRONCHODILATOR AGENTS; DATABASES, FACTUAL; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; ONTARIO; OPIOID-RELATED DISORDERS; PNEUMONIA; PROBABILITY; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84986238372     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01967-2015     Document Type: Article

References (41)

1. Vozoris NT, Wang X, Fischer HD, et al. Incident opioid drug use among older adults with chronic obstructive pulmonary disease: a population-based cohort study. Br J Clin Pharmacol 2016; 81: 161-170.
2. Edmonds P, Karlsen S, Khan S, et al. A comparison of the palliative care needs of patients dying from chronic respiratory diseases and lung cancer. Palliat Med 2001; 15: 287-295.
3. Elkington H, White P, Addington-Hall J, et al. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med 2005; 19: 485-491.
4. Borge CR, Wahl AK, Moum T. Pain and quality of life with chronic obstructive pulmonary disease. Heart Lung 2011; 40: e90-e101.
5. Klink ME, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest 1987; 91: 540-546.
6. Cormick W, Olson LG, Hensley MJ, et al. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax 1986; 41: 846-854.
7. Elkington H, White P, Addington-Hall J, et al. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med 2005; 19: 485-491.
8. Gray PA, Rekling JC, Bocchiaro CM, et al. Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the preBotzinger complex. Science 1999; 286: 1566-1568.
9. Montandon G, Qin W, Liu H, et al. PreBotzinger complex neurokinin-1 receptor-expressing neurons mediate opioid-induced respiratory depression. J Neurosci 2011; 31: 1292-1301.
10. Lalley PM. Opioid receptor agonist effects on medullary respiratory neurons in the cat: evidence for involvement in certain types of ventilatory disturbances. Am J Physiol Regul Integr Comp Physiol 2003; 285: R1287-R1304.
11. Weil JV, McCullough RE, Kline JS, et al. Diminished ventilatory response to hypoxia and hypercapnia after morphine in normal man. N Engl J Med 1975; 292: 1103-1106.
12. Adcock JJ, Schneider C, Smith TW. Effects of codeine, morphine and a novel opioid pentapeptide BW443C, on cough, nociception and ventilation in the unanaesthetized guinea-pig. Br J Pharmacol 1988; 93: 93-100.
13. Vallejo R, de Leon-Casasola O, Benyamin R. Opioid therapy and immunosuppression: a review. Am J Ther 2004; 11: 354-365.
14. Woodcock AA, Gross ER, Gellert A, et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981; 305: 1611-1616.
15. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in pink puffers. Br Med J (Clin Res Ed) 1983; 286: 675-677.
16. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-944.
17. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003; 327: 523-528.
18. Currow DC, McDonald C, Oaten S, et al. Once-daily opioids for chronic dyspnea: a dose increment and pharmacovigilance study. J Pain Symptom Manage 2011; 42: 388-399.
19. Rocker GM, Simpson AC, Joanne Young BHSc, et al. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients' experiences and outcomes. CMAJ Open 2013; 1: E27-E36.
20. Ekström M, Bornefalk-Hermansson A, Currow DC. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. BMJ 2014; 348: g445.
21. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008; 177: 912-927.
22. Mahler DA, Selecky PA, Harrod CG, et al. American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease. Chest 2010; 137: 674-691.
23. Marciniuk D, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011; 18: 69-78.
24. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2014. www.goldcopd.com/uploads/users/files/GOLD-Report-2014-Oct30.pdf Date last accessed: January, 2015.
25. Gershon AS, Wang C, Guan J, et al. Identifying individuals with physician diagnosed COPD in health administrative databases. J COPD 2009; 6: 388-394.
26. Levy R, O'Brien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 2003; 10: 67-71.
27. Gershon AS, Wang C, Wilton AS, et al. Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study. Arch Intern Med 2010; 170: 560-565.
28. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Inter Med 2008; 168: 1090-1096.
29. Vozoris NT, Fischer HD, Wang X, et al. Benzodiazepine drug use and adverse respiratory outcomes among older adults with COPD. Eur Respir J 2014; 44: 332-340.
30. Austin PC. An Introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
31. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015; 34: 3661-3679.
32. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138.
33. Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-1097.
34. Wen SW, Hernandez R, Naylor CD. Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. JAMA 1995; 274: 1687-1691.
35. Greenfield S. The state of outcomes research: are we on target? N Engl J Med 1989; 320: 1142-1143.
36. Austin PC. The performance of different propensity-score methods for estimating marginal hazard ratios. Stat Med 2013; 32: 2837-2849.
37. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959-967.
38. Herings RM, Stricker BH, de Boer A, et al. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155: 1801-1807.
39. Argoff CE, Silvershein Di. A comparison of long-and short-acting opioids for the treatment of chronic noncancer pain: tailoring therapy to meet patient needs. Mayo Clin Proc 2009; 84: 602-612.
40. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
41. Stein BD, Bautista A, Schumock GT, et al. The validity of International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes for identifying patients hospitalized for COPD exacerbations. Chest 2012; 141: 87-93.